AU2003210598A1 - Treatment of sleep disorders using sleep target modulators - Google Patents

Treatment of sleep disorders using sleep target modulators Download PDF

Info

Publication number
AU2003210598A1
AU2003210598A1 AU2003210598A AU2003210598A AU2003210598A1 AU 2003210598 A1 AU2003210598 A1 AU 2003210598A1 AU 2003210598 A AU2003210598 A AU 2003210598A AU 2003210598 A AU2003210598 A AU 2003210598A AU 2003210598 A1 AU2003210598 A1 AU 2003210598A1
Authority
AU
Australia
Prior art keywords
compound
group
therapeutic compound
therapeutic
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210598A
Other languages
English (en)
Other versions
AU2003210598A2 (en
Inventor
David G Hangauer
Harry Jefferson Leighton
Dale M Edgar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hypnion Inc
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of AU2003210598A2 publication Critical patent/AU2003210598A2/en
Publication of AU2003210598A1 publication Critical patent/AU2003210598A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003210598A 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators Abandoned AU2003210598A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34991202P 2002-01-18 2002-01-18
US60/349,912 2002-01-18
US35732002P 2002-02-15 2002-02-15
US60/357,320 2002-02-15
PCT/US2003/001845 WO2003068148A2 (en) 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators

Publications (2)

Publication Number Publication Date
AU2003210598A2 AU2003210598A2 (en) 2003-09-04
AU2003210598A1 true AU2003210598A1 (en) 2003-09-04

Family

ID=27737408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210598A Abandoned AU2003210598A1 (en) 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators

Country Status (6)

Country Link
US (2) US20030232839A1 (https=)
EP (1) EP1471913A2 (https=)
JP (1) JP2005519073A (https=)
AU (1) AU2003210598A1 (https=)
CA (1) CA2473586A1 (https=)
WO (1) WO2003068148A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
US20080167248A1 (en) * 2004-04-26 2008-07-10 Immuneregen Biosciences, Inc. Anti-Aging Effects Of Substance P
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
WO2007098200A2 (en) 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
EP2197536A1 (en) 2007-10-09 2010-06-23 Imthera Medical, Inc. System and method for neural stimulation
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
ATE522169T2 (de) 2009-10-23 2011-09-15 Gruppo Cimbali Spa Kaffeemaschine mit abgabedruckregulierung und damit zusammenhängendes verfahren
JP2013509943A (ja) 2009-11-10 2013-03-21 イムセラ・メディカル・インコーポレーテッド 舌下神経を刺激して患者の舌の位置を調節するシステム
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
WO2012109216A1 (en) 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US9266881B2 (en) 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
CA2909591C (en) 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
KR102597910B1 (ko) 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
HUE058725T2 (hu) * 2018-04-06 2022-09-28 Basf Se Eljárás aminok elõállítására
WO2024102458A1 (en) * 2022-11-11 2024-05-16 Gilgamesh Pharmaceuticals, Inc. Methods of using trazodone to reverse the effects of 5-ht2a receptor agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders

Also Published As

Publication number Publication date
WO2003068148A3 (en) 2004-04-01
JP2005519073A (ja) 2005-06-30
AU2003210598A2 (en) 2003-09-04
EP1471913A2 (en) 2004-11-03
WO2003068148A2 (en) 2003-08-21
CA2473586A1 (en) 2003-08-21
US20060009465A1 (en) 2006-01-12
US20030232839A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
US20030232839A1 (en) Treatment of sleeping disorders using CNS sleep target modulators
US7355042B2 (en) Treatment of CNS disorders using CNS target modulators
US20040142972A1 (en) CNS target modulators
CZ179598A3 (cs) Nové metody a použití
CN1028756C (zh) 新的吡啶基和嘧啶基衍生物的制备方法
CN101970427A (zh) 治疗疼痛症状及其它失调的方法
US7189757B2 (en) Treatment of sleep disorders using CNS target modulators
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
CN115304590A (zh) 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物
KR20210065944A (ko) Dp 길항제
JP7502429B2 (ja) 神経因性疼痛の治療におけるフェニルキノリノン系誘導体およびフラボノイド系誘導体の使用
JPH06511231A (ja) 2−(ピロリジニル−1−メチル)−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
CN87105791A (zh) 喹唑啉二酮和吡啶并嘧啶二酮及其制备方法
WO2007092334A1 (en) Method of treating sleep disorders
WO2007092333A1 (en) Use of olopatadine for treating sleep disorders
US5180726A (en) 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactams
JPWO2005113501A1 (ja) 神経因性疼痛制御剤組成物
JPH03141257A (ja) ジヒドロピリジン誘導体
KR20090057055A (ko) 옥세핀 유도체
CA1132558A (en) Quinazoline antihypertensives
KR20070018077A (ko) 신경인성 동통제어 조성물
AU2006201053A1 (en) Materials and methods for the treatment of gastroesophageal reflux disease
JP2000507569A (ja) 抗精神病薬ならびに鎮痛薬を製造するための、1,1―ジアルキル―1,2,3,4―テトラヒドロイソキノリンの使用
JPH04208283A (ja) 新規な複素環式化合物およびそれを含有する医薬組成物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2004

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period